fenofibric acid has been researched along with pitavastatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Berezowski, V; Blanquart, C; Duez, H; Fruchart, JC; Glineur, C; Martin, G; Najib-Fruchart, J; Poulain, P; Staels, B | 1 |
1 review(s) available for fenofibric acid and pitavastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for fenofibric acid and pitavastatin
| Article | Year |
|---|---|
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; Cell Line; Culture Media, Serum-Free; Cyclic N-Oxides; DNA-Binding Proteins; Enzyme Inhibitors; Fenofibrate; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Mercaptoethanol; Phosphorylation; Promoter Regions, Genetic; Pyridines; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; rho GTP-Binding Proteins; Signal Transduction; Transcription Factors | 2001 |